Literature DB >> 19625744

Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease.

G Stennis Watson1, Laura D Baker, Brenna A Cholerton, Kristoffer W Rhoads, George R Merriam, Gerard D Schellenberg, Sanjay Asthana, Monique Cherrier, Suzanne Craft.   

Abstract

Both insulin alone and the somatostatin analogue octreotide alone facilitate memory in patients with Alzheimer's disease (AD). Since octreotide inhibits endogenous insulin secretion, the cognitive effects of insulin and octreotide may not be independent. This study tested the individual and interactive effects of insulin and octreotide on memory and plasma growth hormone (GH) levels in older adults. Participants were 16 memory-impaired (AD = 7, amnestic mild cognitive impairment = 9; apolipoprotein E [APOE] epsilon4- [no epsilon4 alleles] = 9, epsilon4+ [1-2 epsilon4 alleles] = 7), and 19 cognitively-intact older adults (APOE epsilon4- = 17, epsilon4+ = 1). On separate days, fasting participants received counterbalanced infusions of: 1) insulin (1 mU.kg(-1).min(-1)) and dextrose to maintain euglycemia; 2) octreotide (150 microg/h); 3) insulin, dextrose, and octreotide; or 4) saline. Story recall was the principal endpoint. Insulin alone facilitated delayed recall for epsilon4- patients, relative to epsilon4+ patients (P = 0.0012). Furthermore, epsilon4- patients with higher Mattis Dementia Rating Scale (DRS) scores had greater octreotide-induced memory facilitation (P = 0.0298). For healthy adults, octreotide facilitated memory (P = 0.0122). Unexpectedly, hyperinsulinemia with euglycemia increased GH levels in healthy controls (P = 0.0299). Thus, insulin and octreotide appear to regulate memory in older adults. APOE epsilon4 genotype modulates responses to insulin and octreotide. Finally, insulin may regulate GH levels during euglycemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625744      PMCID: PMC2842464          DOI: 10.3233/JAD-2009-1165

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  33 in total

Review 1.  Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  Eur J Pharmacol       Date:  2004-04-19       Impact factor: 4.432

2.  Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose.

Authors:  S Craft; S Asthana; J W Newcomer; C W Wilkinson; I T Matos; L D Baker; M Cherrier; C Lofgreen; S Latendresse; A Petrova; S Plymate; M Raskind; K Grimwood; R C Veith
Journal:  Arch Gen Psychiatry       Date:  1999-12

Review 3.  Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia.

Authors:  P Galassetti; S N Davis
Journal:  Clin Sci (Lond)       Date:  2000-11       Impact factor: 6.124

4.  Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype.

Authors:  S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

5.  Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knock-out mice.

Authors:  P Dutar; C Vaillend; C Viollet; J-M Billard; B Potier; A-S Carlo; A Ungerer; J Epelbaum
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

6.  Cytokine-associated emotional and cognitive disturbances in humans.

Authors:  A Reichenberg; R Yirmiya; A Schuld; T Kraus; M Haack; A Morag; T Pollmächer
Journal:  Arch Gen Psychiatry       Date:  2001-05

7.  Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.

Authors:  Kristine B Degn; Birgitte Brock; Claus B Juhl; Christian B Djurhuus; Jaime Grubert; Dennis Kim; Jenny Han; Kristin Taylor; Mark Fineman; Ole Schmitz
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

Review 8.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

9.  Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype.

Authors:  Suzanne Craft; Sanjay Asthana; David G Cook; Laura D Baker; Monique Cherrier; Kristina Purganan; Colby Wait; Andreana Petrova; Shawn Latendresse; G Stennis Watson; John W Newcomer; Gerard D Schellenberg; Aaron J Krohn
Journal:  Psychoneuroendocrinology       Date:  2003-08       Impact factor: 4.905

Review 10.  Insulin and neurodegenerative disease: shared and specific mechanisms.

Authors:  Suzanne Craft; G Stennis Watson
Journal:  Lancet Neurol       Date:  2004-03       Impact factor: 44.182

View more
  10 in total

1.  Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration.

Authors:  Feng Chen; Li Li; Fang Xu; Yan Sun; Feifei Du; Xutao Ma; Chenchun Zhong; Xiuxue Li; Fengqing Wang; Nating Zhang; Chuan Li
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.

Authors:  Jeffrey Cummings; Andrew Ortiz; Janelle Castellino; Jefferson Kinney
Journal:  Eur J Neurosci       Date:  2022-02-06       Impact factor: 3.698

Review 3.  Insulin: an emerging treatment for Alzheimer's disease dementia?

Authors:  Jill K Morris; Jeffrey M Burns
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

4.  Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD.

Authors:  Grazia Tundo; Chiara Ciaccio; Diego Sbardella; Mariaserena Boraso; Barbara Viviani; Massimiliano Coletta; Stefano Marini
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

5.  Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.

Authors:  Emmanuelle Duron; Jean-Sébastien Vidal; Dominique Grousselle; Audrey Gabelle; Sylvain Lehmann; Florence Pasquier; Stéphanie Bombois; Luc Buée; Bernadette Allinquant; Susanna Schraen-Maschke; Christiane Baret; Anne-Sophie Rigaud; Olivier Hanon; Jacques Epelbaum
Journal:  Front Aging Neurosci       Date:  2018-10-01       Impact factor: 5.750

6.  Obesity and Density of the Crystalline Lens: Revisiting a Growing Dilemma.

Authors:  Seyed-Farzad Mohammadi; Mohsen Afarideh; Hadi Z Mehrjardi; Sara Mirhadi
Journal:  Biomed Hub       Date:  2017-01-28

7.  Beneficial effects of octreotide in alcohol-induced neuropathic pain. Role of H 2S, BDNF, TNF-α and Nrf2.

Authors:  Rongqiang Jiang; Hongxia Wei
Journal:  Acta Cir Bras       Date:  2021-05-31       Impact factor: 1.388

8.  Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease.

Authors:  Linda Salem; Nadine Saleh; Gaelle Désaméricq; Katia Youssov; Guillaume Dolbeau; Laurent Cleret; Marie-Laure Bourhis; Jean-Philippe Azulay; Pierre Krystkowiak; Christophe Verny; Françoise Morin; Stéphane Moutereau; Anne-Catherine Bachoud-Lévi; Patrick Maison
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

9.  Growth Hormone: Therapeutic Possibilities-An Overview.

Authors:  Steve Harvey; Carlos G Martinez-Moreno
Journal:  Int J Mol Sci       Date:  2018-07-11       Impact factor: 5.923

Review 10.  Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms.

Authors:  Zenghui Wei; Jagadish Koya; Sandra E Reznik
Journal:  Front Neurosci       Date:  2021-07-19       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.